Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. (Nasdaq: ARDX) is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that address significant unmet medical needs. The company's mission is to enhance the treatment of renal and gastrointestinal diseases through its proprietary drug discovery and design platform.
One of Ardelyx's lead products is tenapanor, which has been developed to reduce the absorption of dietary sodium and phosphorus. It is being investigated for multiple conditions, including hyperphosphatemia in patients with end-stage renal disease on dialysis and irritable bowel syndrome with constipation (IBS-C). The company has made significant strides in these areas, recently gaining FDA approval for tenapanor under the brand names IBSRELA® and XPHOZAH®. IBSRELA is targeted at treating IBS-C, while XPHOZAH is aimed at controlling serum phosphorus levels in patients with chronic kidney disease on dialysis.
Ardelyx has also forged strategic partnerships to extend the reach of its therapies globally. This includes collaborations with Kyowa Kirin in Japan, Fosun Pharma in China, and Knight Therapeutics in Canada. Notably, Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan, while a New Drug Application for the same indication is under review in China.
In its latest financial update, Ardelyx reported strong revenue growth for IBSRELA, achieving approximately $80 million in net product sales revenue for its first full year of commercialization. The company anticipates even higher sales in 2024, projecting revenues between $140 million and $150 million. Additionally, XPHOZAH, which launched in November 2023, recorded $2.5 million in net product sales revenue in its first quarter. To support these products, Ardelyx is investing in expanding its sales team and digital capabilities, as well as enhancing its patient services through the ArdelyxAssist™ program.
As of December 31, 2023, Ardelyx maintained a strong cash position with approximately $184 million in cash, cash equivalents, and short-term investments. The company’s financial stability and continuous investment in its robust R&D pipeline underscore its commitment to advancing the standard of care for patients with renal and gastrointestinal diseases.
Ardelyx continues to engage with the medical community and investors through various platforms, including regular webcasts and conferences. The company remains focused on executing its commercial strategy, expanding market penetration, and exploring new avenues for growth through internal development and external partnerships.
Ardelyx, Inc. (Nasdaq: ARDX) reported its first quarter 2022 results, showing a cash position of $89.7 million, down from $116.7 million in Q4 2021. The company recognized $0.5 million in product sales from IBSRELA, its first FDA-approved product for IBS-C. Collaboration revenue decreased to $18,000 from $6.6 million year-over-year. R&D expenses fell by 56.7% to $8.9 million, while SG&A expenses rose 12.9% to $19.3 million. The net loss for Q1 2022 was $28.1 million ($0.21 per share), an improvement from a $33.2 million loss in Q1 2021. A conference call was scheduled for 4:30 PM ET today.
Ardelyx, Inc. (NASDAQ: ARDX) will hold a conference call on May 5, 2022, at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update. The company, focused on developing innovative medicines, has completed three successful Phase 3 trials for its product candidate XPHOZAH (tenapanor) designed to control serum phosphorus in CKD patients on dialysis. Ardelyx is also advancing treatments for potassium management and metabolic acidosis, with partnered development in Japan, China, and Canada.
Ardelyx announced an interim response from the FDA regarding its appeal for XPHOZAH's New Drug Application (NDA), initially denied in July 2021. The FDA's Office of New Drugs emphasized the need for input from expert clinicians through an Advisory Committee meeting to evaluate the phosphate-lowering effects demonstrated in the Phase 3 trials for XPHOZAH, intended for patients with chronic kidney disease on dialysis. Ardelyx expects a response within 30 days post-meeting.
On April 5, 2022, Ardelyx, Inc. (Nasdaq: ARDX) announced the grant of stock options and Restricted Stock Units (RSUs) to five non-executive employees as an employment inducement. A total of 68,797 stock options and 33,450 RSUs were awarded, with an exercise price of $1.11 per share, equal to the closing trading price on the grant date. Vesting occurs over four years, with 25% vesting annually and the remainder monthly for stock options, while RSUs vest quarterly. This grant aligns with Nasdaq rules and is aimed at incentivizing employee commitment.
On April 11, 2022, Ardelyx, Inc. (Nasdaq: ARDX) announced an amendment to its license agreement with Kyowa Kirin Co. Ltd. concerning tenapanor, intended for treating cardiorenal diseases in Japan. The agreement includes a reduced royalty rate in exchange for a total payment of up to $40 million, contingent on Kyowa Kirin's marketing approval filings. This change will lower the royalty payments from the high teens to mid-single digits over a specified period. Kyowa Kirin plans to file for approval in the second half of 2022 and expects a decision by the second half of 2023.
Ardelyx, Inc. (Nasdaq: ARDX) presented significant findings regarding XPHOZAH at the National Kidney Foundation 2022 Spring Clinical Meetings. Four posters indicated that XPHOZAH improved phosphate management in chronic kidney disease (CKD) patients on dialysis. The OPTIMIZE study showed a substantial proportion of patients achieved target phosphorus levels. The PHREEDOM trial highlighted that 77% of patients experienced phosphate reduction, with 41% achieving a decrease of >2 mg/dL. XPHOZAH is positioned as a first-in-class phosphate absorption inhibitor with a novel mechanism.
Ardelyx has launched IBSRELA® (tenapanor), the first FDA-approved NHE3 inhibitor for treating Irritable Bowel Syndrome with Constipation (IBS-C) in adults. This marks a significant milestone for Ardelyx as it is their first approved product. With successful Phase 3 trials involving over 1,200 patients, IBSRELA demonstrated noticeable improvements in abdominal pain and bowel movements. The company is committed to enhancing patient care through its ArdelyxAssist™ program, which provides access and affordability support for patients and healthcare providers.
On March 9, 2022, Ardelyx, Inc. (Nasdaq: ARDX) announced the grant of stock options and Restricted Stock Units (RSUs) to new non-executive employees. A total of 105,470 options and 71,250 RSUs were allocated to 11 employees. The options have an exercise price of $0.92 per share, equal to the closing stock price on the grant date, and vest over four years. Ardelyx is advancing its innovative drug tenapanor for treating conditions related to chronic kidney disease and has international partnerships for its development. The company plans to launch IBSRELA in Q2 2022.
Ardelyx, a biopharmaceutical company, announced that CEO Mike Raab will participate in a GI/Microbiome panel at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 10:30 AM ET. The event will be held virtually. Ardelyx focuses on developing first-in-class medicines addressing unmet medical needs, including IBSRELA (tenapanor), set to launch in Q2 2022. The company is also advancing treatments for chronic kidney disease, hyperkalemia, and metabolic acidosis. A replay of the panel will be available on their website for 30 days post-event.
Ardelyx, Inc. (Nasdaq: ARDX) reported its fourth-quarter and full-year 2021 financial results, highlighting a revenue increase of 33% to $10.1 million. The company is set to launch IBSRELA for IBS-C treatment in April 2022. Despite a net loss of $158.2 million, Ardelyx is optimistic about achieving breakeven with IBSRELA and potential profitability. The company also announced a new term loan agreement of $27.5 million, extending its cash position to support this launch. Total cash reserves were $116.7 million as of December 31, 2021.
FAQ
What is the current stock price of Ardelyx (ARDX)?
What is the market cap of Ardelyx (ARDX)?
What is Ardelyx, Inc. focused on?
What are the main products of Ardelyx?
How has Ardelyx performed financially in recent years?
What strategic partnerships does Ardelyx have?
What is tenapanor used for?
What is the ArdelyxAssist™ program?
What is the financial status of Ardelyx?
Where can investors find more information about Ardelyx?
What recent achievements has Ardelyx made?
What future plans does Ardelyx have?
